We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Phathom Pharmaceuticals Inc | NASDAQ:PHAT | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.15 | -1.40% | 10.54 | 10.24 | 10.49 | 10.7741 | 10.25 | 10.72 | 533,976 | 21:33:22 |
From May 2023 to May 2024
Guggenheim Securities 5th Annual Inflammation, Neurology & Immunology Conference in New York, NYDate: Tuesday, November 7, 2023Live Webcast: 2:30 p.m. ET Management to participate in one-on-one meetings throughout the conference
Jefferies London Healthcare Conference in London, EnglandDate: Tuesday, November 14, 2023Live Webcast: 10:30 a.m. ETManagement to participate in one-on-one meetings throughout the conference
Stifel 2023 Healthcare Conference in New York, NYDate: Wednesday, November 15, 2023Live Webcast: 2:25 p.m. ETManagement to participate in one-on-one meetings throughout the conference
Craig-Hallum 14th Annual Alpha Select Conference in New York, NYDate: Thursday, November 16, 2023Management to participate in one-on-one meetings throughout the conference
Evercore ISI 6th Annual HealthCONx Conference in Miami, FLDate: Wednesday, November 29, 2023Live Webcast: 4:15 p.m. ETManagement to participate in one-on-one meetings throughout the conference
To access the live webcast and archived recordings of each event, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. Recordings will be available for 90 days following the conclusion of each meeting.
About Phathom Pharmaceuticals, Inc.Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB). For more information about Phathom, visit the Company’s website at www.phathompharma.com and follow the Company on LinkedIn and Twitter.
MEDIA CONTACTNick Benedetto1-877-742-8466media@phathompharma.com
INVESTOR CONTACTEric Sciorilli1-877-742-8466ir@phathompharma.com
© 2023 Phathom Pharmaceuticals. All rights reserved.
1 Year Phathom Pharmaceuticals Chart |
1 Month Phathom Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
